Read by QxMD icon Read

etoposide with cisplatin mCRPC

Matthieu Caubet, Erion Dobi, Astrid Pozet, Hamadi Almotlak, Philippe Montcuquet, Tristan Maurina, Guillaume Mouillet, Thierry N'guyen, Ulrich Stein, Antoine Thiery-Vuillemin, Frederic Fiteni
The combination of cisplatin or carboplatin and etoposide is the standard treatment for certain poorly differentiated neuroendocrine cancers, such as small-cell lung cancer. The aim of this study was to assess the efficacy and tolerability of the carboplatin-etoposide regimen in metastatic castration-resistant prostate cancer (mCRPC). A total of 27 patients treated by carboplatin [area under the curve (AUC)=5] and etoposide (100 mg/m(2) intravenous infusion on days 1-3 or 75 mg orally/day for 10 days) for mCRPC were included for analysis...
November 2015: Molecular and Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"